ELAPSENCT05976685
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Nov 7, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 32 → 35 locations
- Minor Study sites: 33 to 34
- Notable Eligibility criteria expanded, about 24 words
- Study sites: 32 to 33
- Secondary endpoints: details revised at 4 of 12 entries
- Minor Study sites: 31 to 32v19
- Minor Study sites: 30 to 31v18
Show 16 earlier versionsHide 16 earlier versions
- Minor Study sites: 29 to 30v17
- Minor Study sites: 28 to 29v16
- Minor Study sites: 27 to 28v15
- Minor Study sites: 25 to 27v14
- Minor Study sites: 23 to 25v13
- Minor Study sites: 21 to 23v12
- Minor Study sites: 18 to 21v11
- Minor Study sites: 17 to 18v10
- Minor Study sites: 16 to 17v9
- Minor Study sites: 12 to 16v8
- Minor Study sites: 9 to 12v7
- Minor Study sites: 7 to 9v6
- Notable Eligibility criteria shortened, about 21 words
- Site details revised at 2 of 7 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 7
- Notable Start date: Jan 1, 2024 to May 1, 2024
- Eligibility criteria expanded, about 108 words
- Notable Eligibility criteria shortened, about 76 words
- Interventions: DOAC (Drug), Left atrial appendage Occlusion and 3 months of Clopidogrel (Procedure) to DOAC (Drug), Left atrial appendage Occlusion (Procedure)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death (whatever comes first).
Timeframe: 6 months
Secondary (12)
Recurrent ischemic stroke
Systemic embolism
Cardiovascular death
Symptomatic intracranial hemorrhage
Major extracranial bleeding (ISTH)
Show 7 moreShow less
Procedure-related death
Serious device- or procedure-related complication
All-cause hospitalization
Cause-specific hospitalization
Global health
Global safety
Functional neurological outcome
Arms and interventions
LAAO and DOAC therapyExperimental
Left atrial appendage occlusion and therapy with direct oral anticoagulants
DOAC therapy onlyOther
Therapy with direct oral anticoagulants alone
Procedures: Left atrial appendage Occlusion
Drugs: DOAC
Sites
35 sites in 6 countries
Germany 9, Switzerland 8, Belgium 6, Spain 6, United Kingdom 5, New Zealand 1